Search results for "pharmaceutical"

showing 10 items of 3243 documents

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.

2020

Diabetic dyslipidemia, characterized by increased plasma triglycerides and decreased HDL cholesterol levels, is a major factor contributing to nonalcoholic steatohepatitis and cardiovascular risk in type 2 diabetes. Activation of the cannabinoid-1 receptor (CB1R) and activation of inducible nitric oxide synthase (iNOS) are associated with nonalcoholic steatohepatitis progression. Here, we tested whether dual-targeting inhibition of hepatic CB1R and iNOS improves diabetic dyslipidemia in mice with diet-induced obesity (DIO mice). DIO mice were treated for 14 days with (S)-MRI-1867, a peripherally restricted hybrid inhibitor of CB1R and iNOS. (R)-MRI-1867, the CB1R-inactive stereoisomer that …

0301 basic medicineMaleVery low-density lipoproteinEndocrinology Diabetes and MetabolismNitric Oxide Synthase Type II[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB][SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMice0302 clinical medicineReceptor Cannabinoid CB1[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Receptor[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Cells Cultured[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismbiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]Nitric oxide synthaseLiver[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyKexinlipids (amino acids peptides and proteins)medicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]LipoproteinsImmunoblotting030209 endocrinology & metabolismReal-Time Polymerase Chain Reaction03 medical and health sciencesInternal medicineCommentariesInternal MedicinemedicineAnimalsObesity[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Dyslipidemiasbusiness.industry[SDV.OT] Life Sciences [q-bio]/Other [q-bio.OT]PCSK9nutritional and metabolic diseases[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseLipid Metabolism[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMice Inbred C57BL030104 developmental biologyEndocrinologyGlucoseLDL receptorbiology.proteinHepatocytes[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologySteatosisbusinessDyslipidemia
researchProduct

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Impairment of Everyday Spatial Navigation Abilities in Mild Cognitive Impairment Is Weakly Associated with Reduced Grey Matter Volume in the Medial P…

2020

Alzheimer’s Disease Neuroimaging Initiative.

0301 basic medicineMalephysiopathology [Cognitive Dysfunction]positron emission tomographypathology [Cognitive Dysfunction]diagnostic imaging [Cognitive Dysfunction]grid cellsAudiologySpatial memoryVolumetry0302 clinical medicinepathology [Gray Matter]Activities of Daily Livingmagnetic resonance imagingEntorhinal CortexGray MatterAged 80 and overGeneral NeuroscienceGgrid cellsCognitionGeneral MedicineHuman brainOrgan SizeMiddle AgedMagnetic Resonance ImagingPsychiatry and Mental healthClinical Psychologymedicine.anatomical_structureFemalediagnostic imaging [Entorhinal Cortex]Spatial NavigationPositron emission tomographymedicine.medical_specialtyphysiology [Spatial Navigation]spatial navigationGrey matter03 medical and health sciencesAtrophymild cognitive impairmentNeuroimagingFluorodeoxyglucose F18medicineHumansCognitive Dysfunctionddc:610Entorhinal cortexAgedvolumetrybusiness.industrydiagnostic imaging [Gray Matter]Mild cognitive impairmentpathology [Entorhinal Cortex]Entorhinal cortexmedicine.disease030104 developmental biologyPositron-Emission TomographyBrodmann area 34Geriatrics and Gerontology18F-fluorodeoxyglucoseAtrophyRadiopharmaceuticalsbusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct

Phototherapy: Ruthenium-Containing Block Copolymer Assemblies: Red-Light-Responsive Metallopolymers with Tunable Nanostructures for Enhanced Cellular…

2016

0301 basic medicineMaterials scienceNanostructureStimuli responsiveBiomedical EngineeringPharmaceutical Sciencechemistry.chemical_elementNanotechnologyRutheniumBiomaterials03 medical and health sciences030104 developmental biologychemistryDrug deliveryCopolymerSelf-assemblyRed lightAdvanced Healthcare Materials
researchProduct

H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice

2020

Deregulation of the dynamic crosstalk between the gut microbiota, intestinal epithelial cells, and immune cells is critically involved in the development of inflammatory bowel disease and the overgrowth of opportunistic pathogens, including the human opportunistic fungus Candida albicans. In the present study, we assessed the effect of N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), a protein kinase A inhibitor, on the migration of macrophages to C. albicans through dextran sulphate sodium (DSS)-challenged Caco-2 cells. We also investigated the impact of H89 on intestinal inflammation and C. albicans clearance from the gut, and determined the diversity of the gut microbio…

0301 basic medicineMicrobiology (medical)<i>Lactobacillus johnsonii</i>colitisH89030106 microbiologyInflammationGut floraMicrobiologydigestive systemArticleMicrobiology03 medical and health sciences<i>Enterococcus faecalis</i>Immune system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesVirologyCandida albicansmedicineEscherichia coliEnterococcus faecalismicrobiotaColitisCandida albicanslcsh:QH301-705.5Lactobacillus johnsoniiLactobacillus johnsoniiDSSH89;Candida albicans;Escherichia coli;Enterococcus faecalis;Lactobacillus johnsonii;microbiota;DSS;colitis;protein kinase AInnate immune systembiology<i>Escherichia coli</i>[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseasebiology.organism_classificationCorpus albicans3. Good health<i>Candida albicans</i>030104 developmental biologylcsh:Biology (General)[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyprotein kinase Amedicine.symptomMicroorganisms
researchProduct

Molecular epidemiology and drug-resistance mechanisms in carbapenem-resistant Klebsiella pneumoniae isolated in patients from a tertiary hospital in …

2020

Abstract Objectives The aim of this study has been to characterize carbapenem-resistant Klebsiella pneumoniae isolates and to determine the resistance mechanisms involved, the clonal relationship between strains and clinical and demographical data of the infected patients. Methods Clinical and demographical data from patients were collected and statistically analysed. Antimicrobial susceptibility testing was performed and resistance genes were detected both phenotypically and genotypically. Conjugation assays were performed to show horizontal transferability of resistance genes. Clonal relationship was also studied. Next-generation sequencing (NGS) was performed to obtain information regard…

0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaeTetracycline030106 microbiologyImmunologyVirulenceDrug resistanceResistance mechanismsMicrobiologyMicrobiologyTertiary Care Centers03 medical and health sciences0302 clinical medicinePlasmidGenotypemedicineImmunology and AllergyHumans030212 general & internal medicineMolecular EpidemiologyMolecular epidemiologybiologybiology.organism_classificationCarbapenemasesQR1-502Klebsiella InfectionsKlebsiella pneumoniaeCarbapenemsPharmaceutical PreparationsSpainMultilocus sequence typingmedicine.drugJournal of Global Antimicrobial Resistance
researchProduct

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

2017

International audience; Background: Moxifloxacin retains partial activity against some fluoroquinolone-resistant mutants of Mycobacterium tuberculosis. Levofloxacin is presumed to be as active as moxifloxacin against drug-susceptible tuberculosis and to have a better safety profile.Objectives: To compare the in vivo activity of levofloxacin and moxifloxacin against M. tuberculosis strains with various levels of fluoroquinolone resistance.Methods: BALB/c mice were intravenously infected with 106M. tuberculosis H37Rv and three isogenic mutants: GyrA A90V, GyrB E540A and GyrB A543V. Treatment with 50 or 100 mg/kg levofloxacin and 60 or 66 mg/kg moxifloxacin was given orally every 6 h, for 4 we…

0301 basic medicineMicrobiology (medical)Tuberculosis[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationmiceExtensively Drug-Resistant Tuberculosis030106 microbiologyMicrobial Sensitivity TestsMicrobiologyMycobacterium tuberculosis03 medical and health sciences0302 clinical medicine[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationLevofloxacinMoxifloxacinIn vivo[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesmedicineAnimalsPharmacology (medical)heterocyclic compounds030212 general & internal medicinePharmacologyMice Inbred BALB ClevofloxacinbiologyChemistry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationExtensively drug-resistant tuberculosisMycobacterium tuberculosisbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationbacterial infections and mycosesFluoroquinolone resistanceAnti-Bacterial Agents3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesDisease Models AnimalSafety profileTreatment OutcomeInfectious Diseasestuberculosis[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesbacteriamoxifloxacinFluoroquinolonesmedicine.drug
researchProduct

Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics

2021

Essential oils (EOs) or their components are widely used by inhalation or nebulization to fight mild respiratory bacterial infections. However, their interaction with antibiotics is poorly known. In this study we evaluated the effects of citral, the main component of lemongrass oil, on in vitro susceptibility of Pseudomonas aeruginosa to antibiotics. Exposure of strain PA14 to subinhibitory concentrations of citral increased expression of operons encoding the multidrug efflux systems MexEF-OprN and MexXY/OprM, and bacterial resistance to anti-pseudomonal antibiotics including imipenem (twofold), gentamicin (eightfold), tobramycin (eightfold), ciprofloxacin (twofold), and colistin (≥128-fold…

0301 basic medicineMicrobiology (medical)antibiotic resistancemedicine.drug_class[SDV]Life Sciences [q-bio]030106 microbiologyAntibioticsmedicine.disease_causeCitralMicrobiologyMicrobiology03 medical and health scienceschemistry.chemical_compoundtobramycin-citral Schiff baseTobramycinmedicine[CHIM]Chemical Sciencesessential oilscitralOriginal ResearchPseudomonas aeruginosaChemistryAminoglycosidecolistin-citral Schiff baseSciences du Vivant [q-bio]/Microbiologie et Parasitologie[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyeffluxQR1-5023. Good health030104 developmental biology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPseudomonas aeruginosaColistin[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyGentamicinEfflux[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.drugFrontiers in Microbiology
researchProduct

Chemoselective Dual Labeling of Native and Recombinant Proteins

2017

The attachment of two different functionalities in a site-selective fashion represents a great challenge in protein chemistry. We report site specific dual functionalizations of peptides and proteins capitalizing on reactivity differences of cysteines in their free (thiol) and protected, oxidized (disulfide) forms. The dual functionalization of interleukin 2 and EYFP proceeded with no loss of bioactivity in a stepwise fashion applying maleimide and disulfide rebridging allyl-sulfone groups. In order to ensure broader applicability of the functionalization strategy, a novel, short peptide sequence that introduces a disulfide bridge was designed and site-selective dual labeling in the presenc…

0301 basic medicineModels MolecularBiomedical EngineeringPharmaceutical ScienceBioengineering010402 general chemistry01 natural scienceslaw.inventionCell LineMaleimides03 medical and health scienceschemistry.chemical_compoundMiceBacterial ProteinslawAnimalsHumansReactivity (chemistry)CysteineSulfhydryl CompoundsSulfonesMaleimidePeptide sequenceDual labelingPharmacologychemistry.chemical_classificationStaining and LabelingCommunicationOrganic ChemistryDisulfide bondProteinsCombinatorial chemistryRecombinant Proteins0104 chemical sciencesAllyl CompoundsLuminescent Proteins030104 developmental biologychemistryThiolRecombinant DNASurface modificationInterleukin-2PeptidesBiotechnologyBioconjugate Chemistry
researchProduct

Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.

2018

Nonsense mutations in the CFTR gene prematurely terminate translation of the CFTR mRNA leading to the production of a truncated protein that lacks normal function causing a more severe form of the cystic fibrosis (CF) disease. About 10% of patients affected by CF show a nonsense mutation. A potential treatment of this alteration is to promote translational readthrough of premature termination codons (PTCs) by Translational Readthrough Inducing Drugs (TRIDs) such as PTC124. In this context we aimed to compare the activity of PTC124 with analogues differing in the heteroatoms position in the central heterocyclic core. By a validated protocol consisting of computational screening, synthesis an…

0301 basic medicineModels MolecularCell SurvivalNonsense mutationCystic Fibrosis Transmembrane Conductance RegulatorSettore BIO/11 - Biologia MolecolareContext (language use)OxadiazoleSettore BIO/09 - FisiologiaCystic fibrosis03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineDrug DiscoverymedicineHumansRNA MessengerGenetic disorderPharmacologyMessenger RNAOxadiazolesNonsense mutationDose-Response Relationship DrugMolecular StructureChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryTranslational readthroughPremature termination codonTranslation (biology)Settore CHIM/06 - Chimica OrganicaGeneral Medicinemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeCell biologySettore BIO/18 - Genetica030104 developmental biologyBiological targetCystic fibrosi030220 oncology & carcinogenesisHeLa CellsEuropean journal of medicinal chemistry
researchProduct